These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16098969)

  • 1. Disruption of perlecan binding and matrix assembly by post-translational or genetic disruption of dystroglycan function.
    Kanagawa M; Michele DE; Satz JS; Barresi R; Kusano H; Sasaki T; Timpl R; Henry MD; Campbell KP
    FEBS Lett; 2005 Aug; 579(21):4792-6. PubMed ID: 16098969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exogenous expression of the glycosyltransferase LARGE1 restores α-dystroglycan matriglycan and laminin binding in rhabdomyosarcoma.
    Beltrán D; Anderson ME; Bharathy N; Settelmeyer TP; Svalina MN; Bajwa Z; Shern JF; Gultekin SH; Cuellar MA; Yonekawa T; Keller C; Campbell KP
    Skelet Muscle; 2019 May; 9(1):11. PubMed ID: 31054580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous glucuronyltransferase activity of LARGE or LARGE2 required for functional modification of α-dystroglycan in cells and tissues.
    Inamori K; Willer T; Hara Y; Venzke D; Anderson ME; Clarke NF; Guicheney P; Bönnemann CG; Moore SA; Campbell KP
    J Biol Chem; 2014 Oct; 289(41):28138-48. PubMed ID: 25138275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laminin-6 assembles into multimolecular fibrillar complexes with perlecan and participates in mechanical-signal transduction via a dystroglycan-dependent, integrin-independent mechanism.
    Jones JC; Lane K; Hopkinson SB; Lecuona E; Geiger RC; Dean DA; Correa-Meyer E; Gonzales M; Campbell K; Sznajder JI; Budinger S
    J Cell Sci; 2005 Jun; 118(Pt 12):2557-66. PubMed ID: 15928048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Like-acetylglucosaminyltransferase (LARGE)-dependent modification of dystroglycan at Thr-317/319 is required for laminin binding and arenavirus infection.
    Hara Y; Kanagawa M; Kunz S; Yoshida-Moriguchi T; Satz JS; Kobayashi YM; Zhu Z; Burden SJ; Oldstone MB; Campbell KP
    Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17426-31. PubMed ID: 21987822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-translational maturation of dystroglycan is necessary for pikachurin binding and ribbon synaptic localization.
    Kanagawa M; Omori Y; Sato S; Kobayashi K; Miyagoe-Suzuki Y; Takeda S; Endo T; Furukawa T; Toda T
    J Biol Chem; 2010 Oct; 285(41):31208-16. PubMed ID: 20682766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy.
    Okuma H; Hord JM; Chandel I; Venzke D; Anderson ME; Walimbe AS; Joseph S; Gastel Z; Hara Y; Saito F; Matsumura K; Campbell KP
    Elife; 2023 Feb; 12():. PubMed ID: 36723429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal glycosylation of dystroglycan in human genetic disease.
    Hewitt JE
    Biochim Biophys Acta; 2009 Sep; 1792(9):853-61. PubMed ID: 19539754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inside and out of dystroglycan post-translational modification.
    Moore CJ; Winder SJ
    Neuromuscul Disord; 2012 Nov; 22(11):959-65. PubMed ID: 22770978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies.
    Barresi R; Michele DE; Kanagawa M; Harper HA; Dovico SA; Satz JS; Moore SA; Zhang W; Schachter H; Dumanski JP; Cohn RD; Nishino I; Campbell KP
    Nat Med; 2004 Jul; 10(7):696-703. PubMed ID: 15184894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies.
    Michele DE; Barresi R; Kanagawa M; Saito F; Cohn RD; Satz JS; Dollar J; Nishino I; Kelley RI; Somer H; Straub V; Mathews KD; Moore SA; Campbell KP
    Nature; 2002 Jul; 418(6896):417-22. PubMed ID: 12140558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding.
    Yoshida-Moriguchi T; Yu L; Stalnaker SH; Davis S; Kunz S; Madson M; Oldstone MB; Schachter H; Wells L; Campbell KP
    Science; 2010 Jan; 327(5961):88-92. PubMed ID: 20044576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dystroglycan glycosylation and muscular dystrophy.
    Moore CJ; Hewitt JE
    Glycoconj J; 2009 Apr; 26(3):349-57. PubMed ID: 18773291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LARGE expression augments the glycosylation of glycoproteins in addition to α-dystroglycan conferring laminin binding.
    Zhang Z; Zhang P; Hu H
    PLoS One; 2011 Apr; 6(4):e19080. PubMed ID: 21533062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse.
    Grewal PK; Holzfeind PJ; Bittner RE; Hewitt JE
    Nat Genet; 2001 Jun; 28(2):151-4. PubMed ID: 11381262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LARGE glycans on dystroglycan function as a tunable matrix scaffold to prevent dystrophy.
    Goddeeris MM; Wu B; Venzke D; Yoshida-Moriguchi T; Saito F; Matsumura K; Moore SA; Campbell KP
    Nature; 2013 Nov; 503(7474):136-40. PubMed ID: 24132234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct roles for dystroglycan, beta1 integrin and perlecan in cell surface laminin organization.
    Henry MD; Satz JS; Brakebusch C; Costell M; Gustafsson E; Fässler R; Campbell KP
    J Cell Sci; 2001 Mar; 114(Pt 6):1137-44. PubMed ID: 11228157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dystroglycan matrix receptor function in cardiac myocytes is important for limiting activity-induced myocardial damage.
    Michele DE; Kabaeva Z; Davis SL; Weiss RM; Campbell KP
    Circ Res; 2009 Nov; 105(10):984-93. PubMed ID: 19797173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
    Toda T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.